MedTrace Logo

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

NCT07414953 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-02-17

No results posted yet for this study

Summary

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-10504 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Conditions

Interventions

DRUG

HS-10504

HS-10504 administered orally every day

DRUG

SHR-A2009

SHR-A2009 administered intravenously

DRUG

HS-20122

HS-20122 administered intravenously

DRUG

HS-20117

HS-20117 administered intravenously

DRUG

SHR-1826

SHR-1826 administered intravenously

DRUG

SHR-A2102

SHR-A2102 administered intravenously

Sponsors & Collaborators

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-30
Primary Completion
2027-04-30
Completion
2028-11-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07414953 on ClinicalTrials.gov